ArticleMolecular cancer2017
The landscape of BRAF transcript and protein variants in human cancer.
Article in Molecular cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- Article
- BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Molecular biomedicine · 2026Review
- Landscape of BRAF transcript variants in human cancer.Molecular oncology · 2025Article
- Investigating the sources of variable impact of pathogenic variants in monogenic metabolic conditions.Nature communications · 2025Article
- Correction: The landscape of BRAF transcript and protein variants in human cancer.Molecular cancer · 2025Article
- The Raf/LIN-45 C-terminal distal tail segment negatively regulates signaling in Caenorhabditis elegans.Genetics · 2024Article
- A Comprehensive Revision of Radiation Immunotherapy and the Abscopal Effect in Central Nervous System Metastases: Reassessing the Frontier.Current issues in molecular biology · 2024Review
- Evaluation of Fluctuations ofMicroRNA (Shariqah, United Arab Emirates) · 2024Article
- Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma.Cell & bioscience · 2023Article
- PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation.Journal of hematology & oncology · 2023Article
- Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors.Biomedicines · 2022Review
- Harnessing the predictive power of preclinical models for oncology drug development.Nature reviews. Drug discovery · 2022Review
- Clinical efficacy with dabrafenib and trametinib in a T599_V600insT poorly differentiated metastatic thyroid carcinoma.BMJ case reports · 2021Article
- Genetic alteration of Chinese patients with rectal mucosal melanoma.BMC cancer · 2021Article
- High-Throughput Identification of miRNA-Target Interactions in Melanoma Using miR-CATCHv2.0.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Inducible modulation of miR-204 levels in a zebrafish melanoma model.Biology open · 2020Article
- RNA-biology ruling cancer progression? Focus on 3'UTRs and splicing.Cancer metastasis reviews · 2020Review
- Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours.Journal of oncology · 2020Review
- Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test.Disease markers · 2020Article
- Systemic therapy for brain metastases.Critical reviews in oncology/hematology · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
23 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundThe BRAF protein kinase is widely studied as a cancer driver and therapeutic target. However, the regulation of its expression is not completely understood.
resultsTaking advantage of the RNA-seq data of more than 4800 patients belonging to 9 different cancer types, we show that BRAF mRNA exists as a pool of 3 isoforms (reference BRAF, BRAF-X1, and BRAF-X2) that differ in the last part of their coding sequences, as well as in the length (BRAF-ref: 76 nt; BRAF-X1 and BRAF-X2: up to 7 kb) and in the sequence of their 3'UTRs. The expression levels of BRAF-ref and BRAF-X1/X2 are inversely correlated, while the most prevalent among the three isoforms varies from cancer type to cancer type. In melanoma cells, the X1 isoform is expressed at the highest level in both therapy-naïve cells and cells with acquired resistance to vemurafenib driven by BRAF gene amplification or expression of the Δ[3-10] splicing variant. In addition to the BRAF-ref protein, the BRAF-X1 protein (the full length as well as the Δ[3-10] variant) is also translated. The expression levels of the BRAF-ref and BRAF-X1 proteins are similar, and together they account for BRAF functional activities. In contrast, the endogenous BRAF-X2 protein is hard to detect because the C-terminal domain is selectively recognized by the ubiquitin-proteasome pathway and targeted for degradation.
conclusionsBy shedding light on the repertoire of BRAF mRNA and protein variants, and on the complex regulation of their expression, our work paves the way to a deeper understanding of a crucially important player in human cancer and to a more informed development of new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.